Your Global Leader in Stem Cell Market Research
Cell and gene therapy conferences have been rapidly multiplying over the past decade. This article is your ultimate guide to cell and gene therapy conferences worldwide. These conferences include presentations on stem cells, CAR-T, exosomes, and other types of cell and gene therapy applications.
Our goal is for this to be a comprehensive guide to cell and gene therapy events worldwide, so we welcome new additions in the comments below. [Read more…]
Allogene Therapeutics, a clinical-stage biotechnology company pioneering the development of allogeneic CAR T therapies for cancer, announced that it completed a $120 million private financing of Convertible Notes.
According to the company, “Allogene is advancing its allogeneic CAR T cell portfolio, which includes rights to 16 preclinical CAR T cell therapy targets and U.S. rights to UCART19, an allogeneic CAR T cell therapy candidate that is being developed for the treatment of CD19-expressing hematological malignancies. In partnership with Servier, UCART19 is in Phase 1 development for the treatment of relapsed/refractory acute lymphoblastic leukemia (ALL).” [Read more…]
DORVAL, QC, Sept. 6, 2018 – Novartis is pleased to announce that following a Priority Review, Health Canada has approved Kymriah™ (tisagenlecleucel/ CTL019) the first chimeric antigen receptor T cell (CAR-T) therapy to receive regulatory approval in Canada.
Kymriah, a CD19-directed genetically modified autologous T-cell immunocellular therapy, is approved to treat two life-threatening cancers that have limited treatment options and historically poor outcomes, demonstrating the critical need for new therapies for these patients. [Read more…]
CELLforCURE is a French pharmaceutical group that is authorized to do CAR-T manufacturing at its bioproduction site in Les Ulis (Essonne). CELLforCURE holds two Good Manufacturing Practice (GMP) certificates that allows it to manufacture experimental and commercial cell and gene therapies.
On July 10, 2018, CELLforCURE signed an agreement to manufacture CAR-T products for Novartis. Under the terms of the agreement, CELLforCURE will produce cancer CAR-T therapies (“chimeric antigen receptor T-cells”).
Production is scheduled to begin in 2019 following transfer of Novartis’ CAR-T manufacturing technology to CELLforCURE. [Read more…]
NEW YORK and MELBOURNE, Australia, May 29, 2018 — Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that it has entered into a partnership with Cartherics Pty Ltd to develop allogeneic ‘off-the-shelf’ CAR-T cells armed with multiple targeting receptors for use in solid cancers. Off the shelf CAR-T therapies have the potential to reduce costs dramatically and open up this very effective treatment to millions of cancer patients across the world. The initial targets are relapsed ovarian and gastric cancers. Mesoblast and Cartherics will jointly own the intellectual property produced using their combined technologies. [Read more…]
